ResMed Inc (0KW4.L) Q4 2025 Earnings Report

ResMed reported a solid Q4 2025, with revenue of $1.348B, up 10.2% year over year and 4.36% quarter over quarter. The company delivered strong profitability, with gross profit of $820.1M and a net income of $379.7M, translating to a net margin of 28.2% and an EPS of $2.59. Operating income of $454.5M produced an operating margin of approximately 33.7%. Cash generation remained robust, evidenced by operating cash flow of $538.8M and free cash flow of $508.2M, supporting meaningful capital allocation to dividends, share repurchases and selective equity-related activities, while preserving a sizable cash position and a net cash balance of about $327.1M. The balance sheet remains solid, with total assets near $8.17B and total liabilities around $2.21B, underscoring a prudent financial posture as the company expands its Sleep & Respiratory Care devices alongside its expanding Software as a Service (SaaS) platform. Cash and equivalents stand at $1.21B, current ratio at 3.44 and quick ratio at 2.53, signaling ample liquidity to fund near-term needs and strategic investments.